Please login to the form below

Not currently logged in
Email:
Password:

Helsinn Therapeutics names Paul Rittman as CEO

He replaces William Mann, who stepped down on 28 February

Helsinn, a Swiss pharmaceutical group focused on cancer care products, has appointed Paul Rittman as its new chief executive officer.

Rittman, who succeeds William Mann, takes up his new role on 5 March and has pharmaceutical industry experience from previous commercial and general management roles.

Riccardo Bragila, vice chairman and chief executive officer for Helsinn Group, said: “I am delighted to welcome aboard Paul Rittman, who has over 30 years’ experience in pharmaceutical sales and marketing with oncology and across a range of disease areas in North America.

“I am sure his expertise, experience and network will prove invaluable in this key commercial moment for the Helsinn Group.”

Rittman most recently served as senior vice president and general manager, US oncology, leading Teva Pharmaceuticals’ oncology activities for its branded products operations.

Prior to his time at Teva, he also held a number of other senior commercial roles at Intrabiotics and Aventis.

Rittman said: “I have always been impressed with Helsinn’s core values of quality, integrity and respect and so I am delighted to be joining at this time.

“Helsinn is an international pharmaceutical business strongly committed to growth through investing in oncology while working to improve the everyday lives of people with cancer.”

1st March 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...